The National Institute for Health and Clinical Excellence (NICE) has issued guidance on the use of omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11. The following recommendations have been made (taken directly from source):

• Omalizumab is not recommended for the treatment of severe persistent allergic asthma in children aged 6 to 11 years.
• Children currently receiving omalizumab for the treatment of severe persistent allergic asthma should have the option to continue treatment until it is considered appropriate to stop. This decision should be made jointly by the clinician and the child and/or the child’s parents or carers.